Which peptides are in the HHS compounding policy of October 30, 2026?

Short answer

Six peptides are listed in Appendix A of HHS’s October 30, 2026 draft enforcement-discretion policy: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.1 No other substance profiled here is in it.1

Each entry below quotes its profile and links to the full answer there.

In the policy 6

Reviewed by FDA for compounding, but not in the policy 15

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  2. 2
    FDA briefing document for BPC-157-related bulk drug substances ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  4. 4
    FDA briefing document for epitalon ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    FDA briefing document for KPV ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  6. 6
    FDA briefing document for MOTS-c ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  7. 7
    FDA briefing document for Semax ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  8. 8
    FDA briefing document for TB-500 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  9. 9
    FDA evaluation of AOD-9604-related bulk drug substances, November 5, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  10. 10
    December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  11. 11
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  12. 12
    Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗

    U.S. Department of Justice · Official source · Source checked July 22, 2026

  13. 13
    FDA briefing document for emideltide (DSIP) (free base) and emideltide acetate ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026

  14. 14
    503A bulk drug substances under evaluation · GHK-Cu except injectable routes · updated May 14, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked July 22, 2026

  15. 15
    FDA evaluation of kisspeptin-10, July 5, 2024 (briefing document for the October 29, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  16. 16
    October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  17. 17
    Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3) · updated May 14, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  18. 18
    FDA evaluation of thymosin alpha-1-related bulk drug substances, November 15, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026